Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Burning Rock Biotech Limited is a molecular diagnostics company focused on precision oncology, operating primarily in the biotechnology and clinical diagnostics industries. The company develops and commercializes next-generation sequencing (NGS)-based cancer diagnostics that support clinical decision-making, therapy selection, and drug development. Its offerings are used by hospitals, physicians, and pharmaceutical companies to guide targeted cancer treatments and research programs.
The company generates revenue mainly through oncology testing services, in-hospital diagnostic solutions, and pharmaceutical research services. Burning Rock is positioned as a leading independent precision oncology testing provider in China, with strategic advantages in proprietary NGS panels, bioinformatics capabilities, and extensive clinical data assets. Founded in 2014, the company expanded rapidly alongside the adoption of precision medicine in China and completed an initial public offering on the NASDAQ in 2020 under the ticker BNR.
Business Operations
Burning Rock operates through three primary business segments: Central Laboratory Services, In-Hospital Solutions, and Pharmaceutical Research & Development Services. The Central Laboratory Services segment provides comprehensive NGS-based cancer testing performed in company-operated laboratories. In-Hospital Solutions deliver testing instruments, reagents, and technical support that enable hospitals to conduct NGS testing on-site. The Pharmaceutical Research & Development Services segment supports drug discovery, clinical trial enrollment, companion diagnostics development, and biomarker analysis for biopharmaceutical companies.
Operations are primarily domestic, with most revenue generated in China. The company controls proprietary testing platforms, bioinformatics pipelines, and clinically validated gene panels. Its main operating subsidiary is Burning Rock Dx (Guangzhou) Ltd., which holds laboratory accreditations and licenses required for clinical testing. Burning Rock maintains long-term collaborations with hospitals, academic medical centers, and pharmaceutical companies; no material joint ventures have been conclusively disclosed in public filings.
Strategic Position & Investments
Burning Rock’s strategy centers on expanding its role in China’s precision oncology ecosystem by deepening hospital penetration, increasing pharmaceutical partnerships, and enhancing technology platforms. Growth initiatives include expanding in-hospital testing adoption, broadening test menus to cover additional tumor types, and integrating real-world clinical data into oncology research services. The company also emphasizes companion diagnostics development aligned with targeted therapies.
Investment priorities include advanced NGS technologies, artificial intelligence–assisted bioinformatics, and large-scale clinical data infrastructure. Burning Rock participates in multiple oncology drug development programs through service agreements rather than equity ownership. Public disclosures do not consistently identify material acquisitions; where referenced, data on completed acquisitions is inconclusive based on available public sources.
Geographic Footprint
Burning Rock is headquartered in Guangzhou, China, and its operations are concentrated across Mainland China, serving hospitals and pharmaceutical clients nationwide. The company has established a broad domestic laboratory and hospital network, giving it coverage across major economic and medical hubs.
Internationally, Burning Rock’s presence is limited and primarily related to supporting multinational pharmaceutical clients conducting clinical trials in China. The company does not report significant overseas laboratory operations, and its international influence is mainly indirect through cross-border research collaborations and its status as a U.S.-listed public company.
Leadership & Governance
Burning Rock was founded by Jian Mao, who continues to shape the company’s strategic direction with a focus on scientific rigor, clinical relevance, and scalable precision medicine solutions. The leadership team emphasizes long-term partnerships with healthcare providers and pharmaceutical companies, alongside disciplined investment in technology and data capabilities.
Key executives include:
- Jian Mao – Chairman of the Board and Chief Executive Officer
- Jian Li – Chief Financial Officer
- Ming Chen – Chief Medical Officer
- Wenwei Jiang – Chief Operating Officer
The company operates under a board-led governance structure consistent with U.S. public company standards, with oversight of strategy, risk management, and regulatory compliance.